Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

The following are my personal beliefs on why the F

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155380
(Total Views: 554)
Posted On: 06/03/2020 2:15:01 PM
Posted By: 10Blade
The following are my personal beliefs on why the FDA said it would stop approving eIND requests for Leronlimab.
1. It is my understanding that 71 eINDs were approved for Leronlimab and according to my memory Dr. Lalezari had mentioned yesterday how it is unprecedented in a drugs history that they knew the effect of a drug from eIND usage even before the drug had started the trial. I believe this high request rate for eIND had a few effects:
A. Having dealt with multiple government agencies. For me it's not a huge stretch of the imagination that what ever secretary or bureaucrat that was approving the applications probably became overwhelmed and complained about the volume and time it takes to process the applications.
B. There were more approved eINDs approved (71) compared to either trial 58/51. Why is this the case. Enrollment criteria? Or maybe the physicians requesting eIND truly believe in the efficacy of the drug and feel it would be unethical to gamble that there is only a 67% chance that the patient they are personally responsible for receives the medication.
C.In my opinion eINDs undercut the FDAs authority and no agency likes it's authority being diminished. How so? If all that needs to be done for a physician to prescribe an unapproved drug is to fill out some paperwork and this happens on a large scale. The FDA becomes a rubber stamp and in some sense makes them moot.

All of the above is just my opinion


(7)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us